News & Perspective

Discovery of the first new botulinum toxin in 40 years is coupled with withholding key data for security reasons.

Clinical trials will test a candidate vaccine for H7N9 flu in varying doses, some with immune boosters.

The tests could be used for detection and to help in drug development.

A new molecular strategy could diffuse some of the controversy over lab-modified flu viruses.

Experts say some properties of H7 viruses may lend themselves to human adaptation.